Legend Biotech Corporation
LEGN
$18.55
-$0.55-2.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.01% | 77.97% | 78.27% | 115.59% | 120.13% |
| Total Other Revenue | -- | -197.50% | -197.37% | -193.83% | -100.00% |
| Total Revenue | 64.01% | 74.75% | 74.76% | 112.48% | 119.99% |
| Cost of Revenue | 26.96% | 27.71% | 17.21% | 18.52% | 23.11% |
| Gross Profit | 1,090.47% | 251.25% | 169.88% | 128.65% | 91.38% |
| SG&A Expenses | 20.15% | 22.79% | 35.45% | 38.57% | 41.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.99% | 26.22% | 22.34% | 24.11% | 28.19% |
| Operating Income | 55.23% | 45.65% | 41.67% | 45.41% | 31.01% |
| Income Before Tax | -78.75% | 35.60% | -5.99% | 57.81% | 69.60% |
| Income Tax Expenses | -24.87% | 544.39% | 1,125.69% | 1,140.82% | 1,113.95% |
| Earnings from Continuing Operations | -67.68% | 31.15% | -14.14% | 53.19% | 65.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.68% | 31.15% | -14.14% | 53.19% | 65.85% |
| EBIT | 55.23% | 45.65% | 41.67% | 45.41% | 31.01% |
| EBITDA | 56.80% | 46.72% | 42.10% | 46.18% | 31.77% |
| EPS Basic | -66.45% | 31.80% | -12.96% | 54.33% | 67.22% |
| Normalized Basic EPS | -81.91% | 37.83% | -2.91% | 59.99% | 71.56% |
| EPS Diluted | -68.33% | 31.58% | -12.86% | 54.40% | 67.27% |
| Normalized Diluted EPS | -77.31% | 36.67% | -4.29% | 59.15% | 70.83% |
| Average Basic Shares Outstanding | 0.83% | 0.84% | 0.90% | 1.71% | 3.88% |
| Average Diluted Shares Outstanding | -1.60% | 3.32% | 3.38% | 4.22% | 6.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |